AN OPEN-LABEL, MULTI-CENTER, EXPANDED ACCESS STUDY OF TRASTUZUMAB DERUXTECAN IN JAPANESE SUBJECTS WITH HER2-POSITIVE ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225138

Enrollment

100

Registered

2020-03-24

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma

Interventions

investigational material(s) Generic name etc : Trastuzumab deruxtecan INN of investigational material : Trastuzumab deruxtecan Therapeutic category code : 42- Antineoplastic agents Dosage and Administ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Has a pathologically documented locally advanced or metastatic adenocarcinoma of gastric or gastroesophageal junction with HER2 positive 2.Has a medical history of at least 2 prior regimens which had to include fluoropyrimidine agent, platinum agent, and trastuzumab 3.Has an ECOG PS of 0 to 1

Exclusion criteria

Exclusion criteria: 1.Has a medical history of clinically significant lung disease 2.Has active central nervous system metastases 3.Has had non-gastric or gastroesophageal junction primary malignancies within 3 years

Design outcomes

Primary

Measure	Time frame
safety Adverse Event	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026